Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Obesity01:24

Obesity

1.2K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.2K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

235
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
235
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

258
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
258
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

175
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
175

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Appropriate translational designs for determining causal force-based (manual therapy) treatment mechanisms.

Musculoskeletal science & practice·2026
Same author

Examining the individual-level impact of neighborhood-level violent crime on resident mental health.

Psychological trauma : theory, research, practice and policy·2026
Same author

Stakeholder Attitudes Toward the Implementation of School-Based, Universal, Mental Health Screening: Student, Caregiver, and Teacher Perspectives.

International journal of environmental research and public health·2025
Same author

The Effects of Psychological Treatments for Chronic Pain on Reducing Opioid Use in People at Risk for Opioid Misuse: A Randomized Feasibility Trial.

Pain practice : the official journal of World Institute of Pain·2025
Same author

Examining photoperiod, chronotype, and adherence as predictors of morning light treatment effects on depression symptoms: A study of five clinical trials.

Journal of affective disorders·2025
Same author

Feasibility of a Mind-Body Program for Chronic Pain: A Randomized Clinical Trial.

JAMA network open·2025
Same journal

New bovine TB strategy for England.

The Veterinary record·2026
Same journal

BVA Scottish Branch's next president.

The Veterinary record·2026
Same journal

Meet your BVA team.

The Veterinary record·2026
Same journal

Celebrating excellence.

The Veterinary record·2026
Same journal

Get CMA compliant with new resources.

The Veterinary record·2026
Same journal

CVS Equine launches health and safety training.

The Veterinary record·2026
See all related articles

Related Experiment Video

Updated: Jan 22, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

938

What causes obesity?

John Burns1

  • 1Burns Pet Nutrition, Ferry Road, Kidwelly, Carmarthenshire SA17 5EJ.

The Veterinary Record
|June 29, 2019
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Acupoint Catgut Embedding Therapy for Abdominal Obesity Treatment
05:18

Acupoint Catgut Embedding Therapy for Abdominal Obesity Treatment

Published on: November 22, 2024

1.4K
An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

1.3K

Related Experiment Videos

Last Updated: Jan 22, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

938
Acupoint Catgut Embedding Therapy for Abdominal Obesity Treatment
05:18

Acupoint Catgut Embedding Therapy for Abdominal Obesity Treatment

Published on: November 22, 2024

1.4K
An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

1.3K